Report Highlights

Clinical data analytics in the U.S.: Competitive Overview

The U.S. clinical data analytics market is concentrated at the top and fragmented below. IQVIA leads in longitudinal claims, prescription and clinical services, while Medidata Solutions dominates electronic trial data capture across large sponsors and Veeva Systems leads sponsor-side clinical data management software. A long tail of specialist firms competes for registry, genomic and site-level work, and no single vendor controls both trial operations and real-world evidence. That fragmentation keeps the market contestable for well-funded entrants.

Domestic firms such as Datavant and Komodo Health control much of the provider-linked data infrastructure, while multinational owners bring capital and global trial networks. Roche acquired Flatiron Health in 2018 and Dassault Systèmes owns Medidata, so foreign parents now shape US product roadmaps. Competitive advantage here depends less on global scale than on access to American provider records, HIPAA-compliant de-identification and fluency with FDA submission standards such as CDISC. Sponsors also favor vendors with US-based data custody.

Demand Drivers Shaping Clinical Data Analytics in the U.S.

FDA acceptance of real-world evidence for regulatory decisions, grounded in the 21st Century Cures Act, is the strongest demand driver. Sponsors now use external control arms and label-expansion datasets, which favors companies holding linked, longitudinal oncology records. Flatiron Health benefits most because its curated oncology database already supports regulatory-grade studies, while Datavant gains as sponsors require privacy-compliant patient matching across claims and EHR sources. Expect this demand to concentrate among vendors with provider access.

Pharmaceutical R&D is shifting toward oncology, rare disease and cell and gene therapies, where trials are smaller and patient identification is harder. This raises demand for trial feasibility and site selection analytics, which Komodo Health and IQVIA sell into both commercial and clinical planning. Value-based payment models add a second stream, since payers and providers need outcomes analytics to manage risk, rewarding firms with deep claims data and reimbursement-linked dashboards.

Competitive Restraints and Market Challenges

Price competition is intensifying as sponsors demand bundled pricing across trial data capture, analytics and real-world datasets. Smaller vendors undercut licensed data prices, compressing margins for providers of curated datasets. Health systems also charge licensing fees for record access and increasingly sign exclusive arrangements that narrow the pool available to rivals. Mid-tier firms without proprietary provider networks or a full-stack trial platform face the sharpest squeeze, and consolidation follows.

Compliance and talent constraints raise entry costs for new competitors. HIPAA, the FTC Health Breach Notification Rule and state privacy statutes such as the California Consumer Privacy Act require costly de-identification and audit infrastructure, while 21 CFR Part 11 validation adds months to every system change. Demand for biostatisticians, data engineers and clinical informaticists exceeds supply, and interoperability gaps across rural hospitals leave data pipelines uneven outside major metropolitan health systems.

Growth Opportunities for Market Players

Community oncology networks and rural hospitals represent the largest untapped data pool, since their records feed few national datasets. Vendors able to connect these sites through FHIR-based interoperability, enabled by the ONC information blocking provisions, can sell linked outcomes data to sponsors and payers at premium pricing. Players with existing provider contracts hold the advantage. Veeva Systems is already extending its Vault platform into real-world data, and Tempus AI is pairing sequencing data with clinical records to target precision oncology.

Post-approval safety surveillance and label expansion studies offer recurring revenue that trial-focused vendors have not captured. FDA's Sentinel system and growing demand for postmarket commitments create work for firms able to run distributed queries across claims and EHR sources. Clario and Parexel are positioned to bundle wearable and patient-reported data with trial services, while AI-driven patient matching for decentralized trials remains underserved by incumbent platforms.

Market at a Glance

Leading Market Participants

• IQVIA
• Medidata Solutions
• Veeva Systems
• Flatiron Health
• Datavant
• Komodo Health
• Oracle Health
• Tempus AI
• Clario
• Parexel

Regulatory and Policy Environment

FDA's real-world evidence framework, anchored in Section 3022 of the 21st Century Cures Act, defines the evidentiary standards that determine which data assets carry regulatory weight. Electronic records used in submissions must satisfy 21 CFR Part 11, and sponsors align data standards with ICH E6(R3) good clinical practice, finalized in 2025. On the interoperability side, the ONC Health Data, Technology and Interoperability rule and its information blocking provisions force EHR vendors to open record access, which lowers barriers for independent analytics firms.

The DOJ bulk sensitive data rule, effective April 2025 under Executive Order 14117, restricts transfers of American health data to countries of concern, which directly limits offshore data processing by foreign-controlled vendors. HIPAA de-identification standards, Washington's My Health My Data Act and the FTC Health Breach Notification Rule define which datasets can be licensed commercially. Competitors must therefore build US-based data custody to win federal and sponsor contracts.

Competitive Outlook for Clinical Data Analytics in the U.S.

By 2032, competitive advantage will concentrate around owners of linked, regulatory-grade data assets. Pharmaceutical parents will continue to acquire data specialists, following Roche's ownership of Flatiron Health, while platform vendors such as Veeva Systems and Medidata Solutions extend from trial operations into real-world evidence. Large EHR vendors will remain gatekeepers of record access, which keeps interoperability fees and exclusivity deals central to pricing. Private equity will keep funding mid-sized data companies seeking acquirers.

Mid-tier specialists without proprietary provider connections or full-stack platforms will face consolidation or niche retreat. Winners will combine AI-driven patient matching, validated workflows and US-based data custody, which the DOJ rule now makes a regulatory requirement for many federal and sponsor contracts. Expect the top five vendors to capture a rising share of revenue, while the specialist tail competes on oncology, rare disease and registry niches.